NYMOX PHARMACEUTICAL CORPORATION
NASDAQ : NYMX

NYMOX PHARMACEUTICAL CORPORATION

January 25, 2006 10:10 ET

Nymox Obtains CE Mark for NicAlert-TM-; Product Now Available in Europe

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Jan 25, 2006) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that NicAlert™, the Company's tobacco exposure test, has achieved certification with the CE Mark. The CE Mark indicates that the product complies with EU safety, environmental, and quality standards and makes the product eligible for sale in the European Union. NicAlert™ previously received clearance from the U.S. Food and Drug Administration for determining smoking status for medical uses in the U.S. Nymox has satisfactorily completed the testing and registration required to obtain CE Marking for the NicAlert™ test.

"The CE Mark opens an important market of 25 countries and over 460 million people for our NicAlert™ product," said Brian Doyle, Nymox's Senior Manager for Worldwide Sales and Marketing. "Tobacco use and exposure has increasingly become a public health priority in Europe as awareness grows about tobacco's terrible toll on lives and health. NicAlert™ offers a quick, convenient, cost-effective way for testing for tobacco product use and exposure."

NicAlert™ uses Nymox's patented technology to provide an easy-to-use, on-site visual read-out of an individual's level of tobacco use or exposure within minutes. The product requires no instruments or special training. Researchers have reported on the accuracy and convenience of the NicAlert™ technology: Journal of Analytical Toxicology (2005; 29: 814-818); Cancer Epidemiology, Biomarkers & Prevention (2002; 11: 1123-1125); and Nicotine & Tobacco Research (2002; 4: 305-9).

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    website: www.nymox.com